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BACKGROUND: Platelet-activating factor (PAF) seems to
be implicated in systemic lupus erythematosus (SLE)
patients with associated renal diseases.Aims: In this
study, we ensured the role of PAF in SLE patients
without renal complications.
Methods: Blood PAF and acetylhydrolase activity,
plasma soluble phospholipase A2, and the presence
of antibodies against PAF were investigated in 17 SLE
patients without active nephritis and in 17 healthy
controls.
Results: Blood PAF levels were not different (p/
0.45) between SLE patients (6.79 /2.8 pg/ml) and
healthy subjects (9.69 /3.1 pg/ml). Plasma acetylhy-
drolase activity (the PAF-degrading enzyme) was
significantly (p/0.03) elevated in SLE patients
(57.89 /6.4 nmol/min/ml) as compared with controls
(37.99 /2.6 nmol/min/ml). Plasma soluble phospholi-
pase A2 (the key enzyme for PAF formation) was not
different (p/0.6) between SLE patients (59.19 /5.1 U/
ml) and controls (54.79 /2.4 U/ml). Antibodies against
PAF were detected only in 3/17 SLE patients. Flow
cytometry analysis did not highlight PAF receptors
on circulating leukocytes of SLE patients.
Conclusion: This clinical study highlights no evi-
dence for a putative important role of PAF in SLE
patients without active nephritis.
Key words: Acetylhydrolase activity, Platelet-activating
factor, Soluble phospholipase A2, Systemic lupus erythe-
matosus
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Introduction
Platelet-activating factor (PAF) is a phospholipid
compound produced by stimulated inflammatory
cells such as monocytes, neutrophils, and eosino-
phils.
1 PAF is not stored in cells, but is derived from a
membrane precursor, 1-alkyl-2-acyl-glycero-3-phos-
phocholine. The action of a phospholipase A2-
dependent process generates the lyso-PAF, and the
subsequent acetylation of the lyso compound results
in the PAF molecule.
1 PAF concentrations are regu-
lated by an acetylhydrolase activity (AHA) found both
in plasma and serum.
2,3 PAF acts through protein-G-
coupled PAF receptors (PAF-R) present on the
membrane of responsive cells.
4 PAF sparks a wide
range of inflammatory actions on various cells and
organs including the kidneys.
5,6 Thus, elevated blood
PAF levels are reported in patients with glomerulone-
phritis
7 and idiopathic immunoglobulin (Ig)A ne-
phropathy.
8
Studies suggest that PAF may play a role in
systemic lupus erythematosus (SLE) patients. Thus,
PAF enhances immunoglobulin production by B
lymphocytes.
9,10 Elevated plasma PAF levels are
reported during the most active phases of the
disease,
11 and monocytes from active SLE patients
produce higher levels of PAF compared with inactive
patients and controls.
12 AHA levels are also affected
in human SLE. Thus, studies report either reduced or
elevated AHA levels in SLE patients as compared with
healthy controls.
11,13 SLE is often characterised by the
development of immune complex glomerulonephri-
tis; lupus nephritis being a leading cause of morbidity
and mortality in SLE.
14 Since the PAF/AHA couple is
deregulated during renal diseases,
5 8 it is difficult to
state whether PAF may be defined as a pathogenic
mediator in SLE or is only the reflection of the
presence of associated diseases, especially renal
ones. Moreover, if abnormal serum lipid profiles are
common in patients with active SLE, they are absent
in SLE patients without renal diseases.
15 In this study,
we investigated blood PAF levels and plasma AHA in
SLE patients without active nephritis. We also as-
sessed their plasma soluble phospholipase A2 (sPLA2)
levels, the presence of antibodies against PAF and the
presence of PAF-R on their peripheral blood cells.
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101Subjects and methods
Subjects
Blood samples were obtained following the Helsinki
recommendations. PAF from whole blood and
plasma AHA levels were investigated in 17 SLE
patients (16 females, one male), aged from 20 to 80
years (mean9 /SEM, 39.29 /4.1 years), without renal
involvement (no proteinuria and haematuria), who
fulfilled the criteria of the American Rheumatism
Association for the diagnosis of SLE,
14 including four
patients with incomplete SLE.
16 At the time of the
study, seven patients had inactive SLE (Systemic
Lupus Erythematosus Disease Activity Index (SLE-
DAI) score 5/3) and 10 had active SLE (SLEDAI score
 /3).
17 Clinical data of SLE patients are reported in
Table 1. Seventeen healthy volunteers (16 females,
one male), aged from 26 to 90 years (mean9 /SEM,
44.09 /4.7 years), were investigated as controls.
PAF and AHA assay
Two millilitres of blood were ethanol extracted,
purified using thin-layer chromatography, and as-
sayed for PAF activity by aggregation of washed
rabbit platelets.
8,18 AHA was assessed by investigating
the degradation of
3H-labeled-PAF.
18
Analysis of PAF-R
Two hundred microlitres of blood were incubated
with PAF-R mouse monoclonal antibodies (Spi Bio,
Massy, France) for 30 min. After washing, cells were
incubated with fluorescein isothiocyanate (FITC)-
labelled goat-anti mouse antibodies (Dakopatts,
Glostrup, Denmark) for 30 min. After washing, cells
were labelled with phycoerythrin (PE)-labelled anti-
CD3, anti-CD19 or anti-CD13 antibodies (Immuno-
tech, Marseille, France) to stain lymphocytic, mono-
cytic and granulocytic populations. The cell
suspension was then submitted to flow cytometric
analysis (XL II, Coulter, Margency, France).
19
Enzyme-linked immunosorbent assay for
antibodies to PAF
This enzyme-linked immunosorbent assay (ELISA)
was performed on plasma samples as previously
described by Tektonidou et al.
20
ELISA for sPLA2
The sPLA2 plasma levels were assessed by ELISA
according to the manufacturer’s recommendations
(R&D Systems Europe, Ltd, Oxon, UK). Results were
expressed as units per millilitre.
Statistical analysis
Differences between groups were assessed using the
Mann /Whitney U-test. pB/0.05 was considered sig-
nificant.
Results
PAF levels in SLE patients
As shown in Fig. 1A, no significant difference (p /
0.45, Mann /Whitney U-test) was documented for
blood PAF levels between SLE patients (6.79 /2.8 pg/
ml, n /17) and a sex-matched and aged-matched
control group of healthy individuals (9.69 /3.1 pg/ml,
n /17). Similarly, no difference was noticed between
blood PAF levels of SLE patients with active or
inactive disease (data not shown). The platelet-
aggregating activity recovered from blood was indis-
Table 1. Clinical and biological data of SLE patients at the time of the investigation
Patient number Sex/age (years) SLEDAI score* Data
$ Medication
1 Female/20 2 1, 2, 5, 6 Hydroxychloroquine; acetyl salicylic acid
2 Female/71 1 1, 4, 6 Prednisolone
3 Male/30 5 1, 2, 6 Hydroxychloroquine; azathioprine
4 Female/33 5 1, 2, 6, 7 Prednisolone; hydroxychloroquine
5 Female/23 4 1, 4, 5, 6 Prednisolone; hydroxychloroquine
6 Female/35 2 1, 2, 6 Hydroxychloroquine
7 Female/25 1 1, 2, 6 None
8 Female/69 11 1, 2, 3, 4, 5, 6, 7 Prednisolone
9 Female/32 3 3, 4, 5, 6, 7 Hydroxychloroquine
10 Female/42 10 4, 6 None
11 Female/80 5 1, 5 Hydroxychloroquine; diclofenac
12 Female/37 4 2, 3, 4, 5, 6, 7 None
13 Female/28 0 4, 5, 6 Prednisolone
14 Female/55 4 1, 2, 4, 5, 6, 7 Hydroxychloroquine; prednisolone
15 Female/49 10 1, 6, 7 Hydroxychloroquine
16 Female/51 12 1, 2, 4, 5, 6, 7 Prednisolone; cyclophosphamide
17 Female/32 2 1, 4, 5, 6, 7 Hydroxychloroquine; acetyl salicylic acid
*SLEDAI, Systemic lupus erythematosus disease activity index.
$1, arthralgia or non-erosive polyarthritis; 2, skin eruption; 3, clinical manifestations of anti-phospholipid syndrome; 4, haematological
disorders; 5, positive anti-DNA antibodies; 6, positive anti-nuclear antibodies; 7, positive anti-phospholipid antibodies.
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physicochemical and biological criteria. First, it
induced in a dose-dependent manner the aggrega-
tion of washed rabbit platelets that were refractory to
arachidonic acid and ADP-mediated pathways; sec-
ond, the platelet aggregating activity was totally
inhibited by 0.1 mM of BN 52021, a specific PAF
receptor antagonist; and third, the aggregating activ-
ity exhibited, on thin-layer chromatography, a reten-
tion time similar to that of synthetic PAF (data not
shown).
AHA level in SLE patients
As shown in Fig. 1B, AHA (the PAF catabolic enzyme)
levels were significantly (p /0.03) elevated in SLE
patients (56.89 /6.4 nmol/min/ml) as compared with
in healthy controls (37.99 /2.6 nmol/min/ml). No
difference was noticed between plasma AHA levels
of SLE patients with active or inactive disease (data
not shown). No correlation between PAF and AHA
levels was observed in SLE patients (r /0.4, p /0.1).
sPLA2 levels in SLE patients
As shown in Fig. 1C, sPLA2 (the key enzyme for the
generation of the PAF precursor, lyso-PAF) levels
were not different (p /0.62) between SLE patients
(59.19 /5.1 U/ml) and healthy controls (54.79 /2.4 U/
ml). No difference was found between sPLA2 levels of
SLE patients with active or inactive disease, and no
correlation between sPLA2 and PAF or AHA levels
were observed (data not shown).
Anti-PAF antibodies in SLE patients
As shown in Fig. 2, antibodies against PAF were
detected in 3/17 (17.6%) patients (two with an active
disease and one with a non-active disease). The
presence of antibodies against PAF was not correlated
with the presence of an anti-phospholipid syndrome
(data not shown).
PAF-R on blood cells of SLE patients
Results of flow cytometry experiments did not high-
light the presence of PAF-R on the membrane of T
and B lymphocytes, monocytes and granulocytes of
SLE patients (data not shown).
Discussion
Studies have reported a role of PAF in SLE patients
with associated renal involvement. Thus, data re-
ported alterations of PAF and AHA levels, and the
presence of antibodies against PAF in SLE pa-
tients.
11,13,20,21 Strengthening clinical results, PAF-R
blockade reduced proteinuria, prevented chronic
glomerular histologic changes and improved survival
in lupus autoimmune mice (lpr and NZBxW
FIG. 1. (A) Blood PAF, (B) plasma AHA and (C) sPLA2 levels in
SLE patients without active nephritis and in healthy controls.
Differences between groups were assessed using the Mann /
Whitney U-test.
FIG. 2. Antibodies against PAF in SLE patients without active
nephritis. Seventeen SLE patients were evaluated in anti-PAF
assays. The upper limit of normal was set at three standard
deviations above the mean of the absorbance values of 17
healthy controls.
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22,23 In this study, we investigated whether PAF
might be involved in SLE patients without active
nephritis.
PAF is routinely measured by a variety of bioassays,
including the platelet-aggregation assay. PAF levels
can also be determined with a radioimmunoassay
(RIA). A good correlation for the measurement of PAF
has been reported between results with the platelet-
aggregation assay and the RIA.
24 Although the RIA
was slightly more sensitive and reproducible than the
platelet-aggregation assay, the bioassay has the
advantage of being rapid and inexpensive. Although
PAF is viewed as a single molecular entity, it is
composed of a C-16:0, C-18:0 and C-18:1 alkyl chain
in the sn-1 position.
25 The length of the 1-0-alkyl
chain has an important effect on the potency of PAF
biological effects. For example, C-18:1 PAF is 100-fold
more potent in decreasing coronary flow than C-18:0
PAF, while C-16:0 PAF is far more potent than C-18:0
PAF to aggregate platelets. The bioassay thus reveals
the total biological aggregating activity of the blood-
derived PAF. In contrast, the RIA has a different
sensitivity for C-16 and C-18 PAF.
26 In this study, we
have used the platelet-aggregation assay to ensure
blood PAF concentrations of SLE patients.
Results of this short clinical study indicate that
blood PAF levels are not increased in SLE patients
without active nephritis. We may speculate that the
elevated PAF levels in SLE patients reported by Tetta
et al.
11 might be linked to their associated renal
diseases rather than to SLE itself. Strengthening this
hypothesis, higher blood PAF levels are reported in
non-SLE patients with glomerulonephritis
7 and idio-
pathic IgA nephropathy.
8 We confirm that AHA levels
are elevated in SLE patients as compared with in
healthy individuals.
13 However, the AHA increase is
modest and sheds little light on its role in SLE patients
since this enzyme is also elevated in several other
non-immune diseases such as asthma, hepatic and
rheumatic diseases, hypertension, diabetes, sepsis
and stroke.
2 Whatever the origin of these elevated
AHA levels, they do not argue in favour of an
important role of PAF in SLE patients without active
nephritis. Phospholipase A2 is the key enzyme for the
synthesis of the PAF precursor, lyso-PAF.
1 Plasma
sPLA2 levels are not changed in SLE patients without
active nephritis. This result is, for another time, not in
favour of a role of PAF in these patients. Similarly to
previous reports,
20,21 anti-PAF antibodies can be
detected in SLE patients. Whatever the function of
anti-PAF antibodies (if any), their low frequency (3/
17 patients) does not argue in favour of an important
role of PAF in SLE patients without active nephritis,
and brings some doubts concerning the usefulness of
their detection in clinical practice. Finally, PAF acts
through PAF-R present on the membrane of respon-
sive cells. PAF is known to enhance, in vitro, the
number of its own receptors on blood cell types such
as monocytes and lymphocytes.
27,28 Speculating that
if PAF acts during SLE it might have a similar effect,
we thus investigated the presence of membrane PAF-
R on circulating blood cells of SLE patients. Our
results indicate that PAF-R is not detected on lym-
phocytes, monocytes and granulocytes of SLE pa-
tients without active nephritis.
In conclusion, blood PAF levels are not elevated in
SLE patients without active nephritis. While their
plasma AHA levels are modestly increased, their
plasma sPLA2 levels are stable and anti-PAF antibo-
dies are not common. Finally, no PAF-R is found on
their circulating leukocytes. Taken together, results of
this clinical study highlight no evidence for a
potential important role of PAF in SLE patients
without active nephritis. However, it must be pointed
out that patients’ medications might have affected
processes leading to PAF formation and/or degrada-
tion. Further experiments investigating the role of
these therapeutical treatments on PAF, sPLA2 and
AHA levels on steady-state conditions could be of
interest to clarify this point.
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